Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory ...

9 September 2026 · By · Wire by Fusion42

Published

9 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 9 September 2026 · Fusion42 review

Full-Life Technologies has received Investigational New Drug (IND) clearance from the U.S. FDA and regulatory clearance in Australia to commence a Phase 1 clinical trial of their [²²⁵Ac]Ac-FL-261 therapy.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech development now has cleared major regulatory hurdles in both the US and Australia, opening a direct route to clinical validation and market entry in two key regions. You should expedite clinical engagement strategies and investor communications around this progress to capitalise on expanded trial access.

◆ Coverage

1 source · 9 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearanceclinical-trialregulatory-approvalphase-1biotech